Piramal Pharma Limited CC-Dec23.pdf · 2024-01-31
A couple of questions. First is on the CDMO business. So, how much of your CDMO business would be from the small biotech firms and how mu ch would it have shifted from small biotech to let's say larger firms or generic pharma over the last few quarters?
The next question is related to the CAPEX. So, we have just completed the large CAPEX of $157-odd million over the last couple of years. So, how much would you need to invest further for growing the business and have the CAPEX plans for FY'25 been fixed?